信立泰SAL0137药品临床试验申请获得受理

Core Viewpoint - The company, Sinopharm, has received approval from the National Medical Products Administration for its clinical trial application of the innovative small molecule drug SAL0137, which is intended for the treatment of elevated lipoprotein (a) levels [1]. Group 1 - The company announced that it has received the acceptance notice for the clinical trial application of SAL0137 [1]. - SAL0137 is an oral small molecule drug developed by the company with independent intellectual property rights [1]. - The clinical trial application submitted by the company is specifically for the treatment of elevated lipoprotein (a) [1].